Somatic mutational landscape in von Hippel–Lindau familial hemangioblastoma
Molecular Oncology · 2026-08 · 20 (8) · 2023-2039
DOI: 10.1002/1878-0261.70228 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Oncology, online erschienen am 23.03.2026. Verfasst von Maja Dembic und 5 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Genome Center, Department of Clinical Research, University of Southern Denmark, Odense, Denmark. Hauptthemen laut MEDLINE: Hemangioblastoma, von Hippel-Lindau Disease, Mutation, Von Hippel-Lindau Tumor Suppressor Protein. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Læge Sofus Carl Emil og Hustru Olga Doris Friis' Legat, Harboefonden, Jacob og Olga Madsens Fond.
Abstract (Originalsprache)
Von Hippel–Lindau disease (vHL) predisposes to tumor development, mainly clear cell renal carcinoma and hemangioblastoma. The underlying cause is germline variants in the VHL gene, with tumorigenesis thought to require additional somatic ‘second‐hit’ events that most commonly include loss of 3p. However, the precise mechanisms of vHL‐related tumor development remain incompletely understood. Genomic investigations of familial hemangioblastoma may help elucidate the early steps of tumorigenesis and contribute to improved disease prediction, biomarker discovery, and therapeutic strategies. We performed whole exome sequencing on 22 familial hemangioblastomas from 7 patients representing 5 unrelated families, and with 4 different causative VHL genotypes. The tumors exhibited low overall mutational burden but showed frequent loss of heterozygosity on chromosome 3 or 3p and single nucleotide variants in the VHL region. Variants were significantly enriched in genes associated with GABAergic and serotonergic neuronal cell types, as well as in pathways regulating cell cycle and neurogenesis. These findings suggest that, in addition to VHL loss, dysregulation of neuronal differentiation programs and cell cycle control may play important roles in hemangioblastoma tumorigenesis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Genome Center, Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
- Department of Clinical Genetics, Odense University Hospital, Odense, Denmark.
- Department of Cellular and Molecular Medicine, University of Copenhagen, Copenhagen, Denmark.
ORCID-Profile: Maja Dembic
Förderung
- Læge Sofus Carl Emil og Hustru Olga Doris Friis' Legat
- Harboefonden
- Jacob og Olga Madsens Fond
Zitieren
APA
Dembic, M., Nørremølle, A., Ousager, L. B., van Brakel Andersen, L., Binderup, M. L. M., & Thomassen, M. (2026). Somatic mutational landscape in von Hippel–Lindau familial hemangioblastoma. Molecular Oncology, 20(8), 2023-2039. https://doi.org/10.1002/1878-0261.70228
Vancouver
Dembic M, Nørremølle A, Ousager LB, van Brakel Andersen L, Binderup MLM, Thomassen M. Somatic mutational landscape in von Hippel–Lindau familial hemangioblastoma. Molecular Oncology. 2026;20(8):2023-2039. doi:10.1002/1878-0261.70228
BibTeX
@article{Dembic2026,
author = {Dembic, Maja and Nørremølle, Anne and Ousager, Lilian Bomme and van Brakel Andersen, Lars and Binderup, Marie Louise Mølgaard and Thomassen, Mads},
title = {Somatic mutational landscape in von Hippel–Lindau familial hemangioblastoma},
journal = {Molecular Oncology},
year = {2026},
volume = {20},
number = {8},
pages = {2023--2039},
doi = {10.1002/1878-0261.70228}
}
EUVIMED